Last updated: August 20, 2026
Ixekizumab, marketed by Eli Lilly as Taltz, generated approximately $2.5 billion in global revenue in 2023. The drug has moved from rapid launch growth to a mature immunology product facing strong competition from IL-17, IL-23, and JAK therapies. Its commercial outlook remains positive through the late 2020s, but revenue growth depends on market-share defense, label expansion, international access, and the timing of biosimilar or follow-on competition.
Taltz is approved for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and pediatric plaque psoriasis. The product’s primary commercial strengths are rapid efficacy, broad inflammatory-disease coverage, and established physician familiarity. Its main risks are the expansion of IL-23 competitors, oral therapies such as upadacitinib, price pressure from U.S. payer negotiations, and eventual follow-on biologic entry.
How much revenue does ixekizumab generate?
Eli Lilly reported Taltz revenue of approximately $2.48 billion in 2023, up from about $2.19 billion in 2021. The product has become one of Lilly’s largest non-diabetes and non-obesity medicines.
| Fiscal year |
Taltz revenue |
Approximate year-over-year change |
| 2019 |
$1.49 billion |
21% |
| 2020 |
$1.82 billion |
22% |
| 2021 |
$2.19 billion |
21% |
| 2022 |
$2.48 billion |
13% |
| 2023 |
$2.48 billion |
Approximately flat |
Sources: Eli Lilly annual reports and Form 10-K filings for the relevant periods.
The trajectory shows three phases:
- Launch expansion from 2016 through 2020. Taltz gained share in plaque psoriasis and entered additional rheumatology indications.
- Scale-up through 2022. New indications and broader reimbursement supported revenue above $2 billion.
- Maturation in 2023. Revenue stabilized as competitive intensity increased and the product faced a larger class of IL-17 and IL-23 therapies.
The 2023 result indicates that Taltz had reached a high-revenue plateau rather than entering an immediate decline phase. Lilly’s revenue base remains large enough to support continued commercial investment, but future growth is likely to be lower than during the first five years after launch.
What is the financial outlook for Taltz?
Taltz’s base-case financial trajectory is stable to moderately declining before biosimilar pressure becomes material. Revenue can remain near the $2 billion level if Lilly maintains U.S. formulary access and preserves share in psoriasis and psoriatic arthritis.
Revenue drivers
The principal revenue drivers are:
- Continued use in moderate-to-severe plaque psoriasis.
- Growth in psoriatic arthritis and axial spondyloarthritis.
- Pediatric adoption following label expansion.
- International reimbursement and commercial execution.
- Physician preference for IL-17 therapy in patients requiring rapid skin clearance.
- Use in patients who fail tumor necrosis factor inhibitors or other biologics.
Revenue constraints
The primary constraints are:
- Increasing preference for IL-23 inhibitors in psoriasis.
- Higher rebate demands from pharmacy benefit managers.
- Biologic switching and step-therapy protocols.
- Competition from oral targeted therapies.
- Loss of exclusivity risk after the late 2020s.
- Potential price erosion from biosimilar or interchangeable follow-on products.
Taltz remains strategically important to Lilly, but its financial role is changing. The product is no longer a principal growth engine comparable to Mounjaro, Zepbound, or newer incretin products. It is more likely to function as a durable cash-flow asset supporting Lilly’s immunology portfolio.
How does ixekizumab compare with competing biologic drugs?
Taltz competes in a crowded inflammatory-disease market. Its most direct competitors are Cosentyx, Tremfya, Skyrizi, Bimzelx, Humira biosimilars, Stelara and its biosimilars, and selected JAK inhibitors.
| Product |
Active ingredient |
Primary class |
Key company |
Competitive position |
| Taltz |
Ixekizumab |
IL-17A inhibitor |
Eli Lilly |
Broad psoriasis and spondyloarthritis label |
| Cosentyx |
Secukinumab |
IL-17A inhibitor |
Novartis |
First-mover IL-17 franchise with broad indications |
| Tremfya |
Guselkumab |
IL-23 inhibitor |
Johnson & Johnson |
Strong psoriasis and psoriatic arthritis growth |
| Skyrizi |
Risankizumab |
IL-23 inhibitor |
AbbVie |
Large psoriasis, Crohn’s disease and ulcerative colitis franchise |
| Bimzelx |
Bimekizumab |
IL-17A/F inhibitor |
UCB |
High efficacy in psoriasis; expanding inflammatory indications |
| Stelara |
Ustekinumab |
IL-12/23 inhibitor |
Johnson & Johnson |
Mature product with biosimilar exposure |
| Rinvoq |
Upadacitinib |
JAK inhibitor |
AbbVie |
Oral option across multiple immune diseases |
| Humira |
Adalimumab |
TNF inhibitor |
AbbVie |
Large installed base but substantial biosimilar erosion |
Taltz versus Cosentyx
Cosentyx is Taltz’s closest mechanistic competitor because both inhibit IL-17A. Cosentyx has earlier market entry, broad rheumatology use and a substantial global commercial base. Taltz competes through rapid skin efficacy, a strong psoriasis profile and Lilly’s commercial infrastructure.
The competitive distinction is increasingly less about mechanism and more about label breadth, dosing convenience, payer positioning, safety management and physician experience.
Taltz versus IL-23 inhibitors
IL-23 therapies have gained share in plaque psoriasis because of durable response, convenient dosing and strong long-term persistence. Skyrizi and Tremfya are the most important threats. Their dosing schedules can be more convenient than Taltz’s maintenance regimen, particularly for patients and providers prioritizing infrequent administration.
Taltz retains advantages in conditions where IL-17 inhibition has a strong clinical role, especially axial spondyloarthritis. It also has a rapid-onset profile that can support use in patients seeking fast symptom or skin improvement.
Taltz versus oral JAK inhibitors
Rinvoq and other JAK inhibitors compete for patients who prefer oral administration or who require treatment across multiple immune-mediated diseases. JAK safety warnings, monitoring requirements and boxed warnings limit their use in some populations, preserving a role for biologics such as Taltz.
What FDA indications support ixekizumab revenue?
The FDA approved Taltz in March 2016 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The label subsequently expanded into psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and pediatric plaque psoriasis.
| FDA milestone |
Approximate timing |
| Initial plaque psoriasis approval |
March 2016 |
| Psoriatic arthritis approval |
2017 |
| Ankylosing spondylitis approval |
2019 |
| Non-radiographic axial spondyloarthritis approval |
2020 |
| Pediatric plaque psoriasis expansion |
2020 |
The indication mix is commercially important. Plaque psoriasis generates the largest patient pool and supports high-volume prescribing. Rheumatology indications reduce dependence on dermatology and provide additional opportunities for patients who fail TNF inhibitors or other targeted treatments.
Taltz’s label does not include inflammatory bowel disease. That limits its addressable market relative to some IL-23 products and JAK inhibitors. IL-17 therapies also require caution in patients with inflammatory bowel disease, which can affect prescribing decisions.
What patents protect ixekizumab and when does Taltz lose exclusivity?
Taltz is a biologic, so its U.S. regulatory protection is governed by the Biologics Price Competition and Innovation Act rather than the conventional small-molecule Hatch-Waxman framework.
The FDA granted Taltz 12 years of reference-product exclusivity under the U.S. biologics regime. Based on the 2016 approval date, the principal U.S. statutory exclusivity period runs to approximately 2028, subject to pediatric exclusivity and the applicable regulatory calculation. Biosimilar applicants may face a separate patent estate that extends beyond the core regulatory exclusivity period.
Orange Book and Purple Book status
Taltz is not listed in the FDA Orange Book as a conventional small-molecule drug. Its biologic reference-product information is recorded through the FDA Purple Book framework. The Purple Book identifies reference products and biosimilar or interchangeable relationships, while patent disputes are handled under the biologics patent litigation process.
Patent categories
The Taltz estate generally covers several layers of intellectual property:
- Antibodies that bind and neutralize interleukin-17A.
- Antibody sequence and molecular structure.
- Cell lines and recombinant production.
- Pharmaceutical formulations.
- Dosage regimens.
- Methods of treating psoriasis and psoriatic arthritis.
- Manufacturing and purification processes.
Core antibody patents may expire before or near the end of the 12-year regulatory exclusivity period, while formulation, process and use patents can create later barriers. The effective protection date depends on patent-term adjustment, patent-term extension, terminal disclaimers, claim scope and the outcome of any validity or infringement dispute.
Public patent records should be reviewed at the individual family and claim level before valuing a specific launch date. A patent’s listing or grant does not establish that every claim will survive an invalidity challenge.
What biosimilar risk exists for ixekizumab?
Through June 30, 2024, no FDA-approved ixekizumab biosimilar had been identified in the FDA Purple Book. The near-term risk is therefore lower than for older biologics such as Humira and Stelara, which had already entered or were approaching biosimilar competition.
The likely U.S. entry sequence is:
- A biosimilar developer files an application under the abbreviated 351(k) pathway.
- The applicant and Lilly exchange patent information under the biologics patent litigation process.
- Litigation or settlement determines whether commercial launch occurs before or after regulatory exclusivity expiration.
- Payers determine whether the product receives preferred formulary status.
- Price erosion develops gradually rather than immediately reaching the levels seen in small-molecule generic markets.
Biosimilar penetration for Taltz will depend on manufacturing complexity, interchangeability status, contracting strategy and the number of approved competitors. Monoclonal antibodies generally face more difficult analytical and manufacturing requirements than conventional generics. That raises development costs and can reduce the number of viable entrants.
Which companies could challenge Taltz exclusivity?
Potential challengers include large biosimilar manufacturers with experience in monoclonal antibodies, including Amgen, Biocon Biologics, Celltrion, Samsung Bioepis, Sandoz, Fresenius Kabi and Pfizer, although a company’s development interest cannot be inferred solely from its existing biosimilar portfolio.
The most credible challengers would have:
- A validated cell-line and antibody-manufacturing platform.
- Global regulatory capabilities.
- U.S. payer contracting capacity.
- Experience litigating biologic patent estates.
- Sufficient scale to absorb development and launch costs.
The absence of an approved biosimilar by mid-2024 does not eliminate later entry risk. It indicates that development, litigation, or commercial timing had not yet produced an approved competitor at that point.
What patent litigation and settlement risks affect Taltz?
Taltz faces the standard litigation risks associated with complex biologics:
- Invalidity challenges against composition-of-matter claims.
- Non-infringement claims involving manufacturing processes.
- Disputes over formulation and dosage patents.
- Challenges to method-of-use claims.
- Patent-term and regulatory-exclusivity disputes.
- Settlement agreements that establish a negotiated launch date.
A settlement could delay biosimilar launch beyond the earliest statutory date while reducing litigation uncertainty. The commercial impact would depend on the number of entrants, the settlement date, any supply restrictions, and whether the agreement permits an authorized follow-on product.
Because Taltz is a biologic, there is no standard paragraph IV certification process identical to the one used for tablets and capsules. Biosimilar applicants instead use the 351(k) pathway and the BPCIA patent-exchange process. References to a "Paragraph IV challenge" for Taltz should therefore be treated as shorthand for a biosimilar patent challenge, not as a technically precise regulatory description.
How strong is the ixekizumab patent estate?
Taltz has a commercially meaningful patent estate because protection is distributed across antibody, formulation, manufacturing and use claims. Its strength is greater than a single-patent product, but the estate is not immune to challenge.
Strengths
- A clinically validated monoclonal antibody with complex manufacturing.
- Multiple disease indications and corresponding method-of-use claims.
- Potential formulation and process barriers.
- Regulatory exclusivity extending to approximately 2028.
- High switching costs for patients who are stable on therapy.
- A large installed base that can support contracting and retention programs.
Weaknesses
- The core product launched in 2016, so the commercial life before U.S. biosimilar risk is finite.
- IL-23 competitors can erode share without infringing ixekizumab patents.
- Method-of-use patents may be narrower than composition claims.
- Manufacturing patents can be designed around.
- Europe may experience biosimilar or follow-on competition on a different schedule from the United States.
Patent strength should therefore be assessed as a combination of legal enforceability and commercial relevance. A strong formulation patent may have limited value if competitors can launch a different formulation. A broad antibody claim may have significant value if it covers the biosimilar molecule itself.
What generic and biosimilar launch scenarios exist for ixekizumab?
Three scenarios are most relevant.
Delayed-entry scenario
A biosimilar launches after 2028 or later following patent settlement. Taltz revenue declines gradually as Lilly uses rebates, patient support and contracting to retain share. This scenario preserves a meaningful portion of the franchise into the early 2030s.
Limited-competition scenario
One or two biosimilars launch, but manufacturing complexity and weak payer incentives limit switching. Net price declines, but volume remains relatively stable. Lilly retains a high-value specialist franchise.
Rapid-erosion scenario
Several biosimilars launch close together, with one obtaining favorable formulary treatment or interchangeability. Net price and volume decline more rapidly. This scenario is less likely to resemble immediate small-molecule generic erosion because biologic substitution is more controlled by physicians and payers.
What geographic markets matter most for ixekizumab?
The United States is the most important market for Taltz profitability because biologic net prices are generally higher and Lilly has direct commercial control. Europe contributes substantial volume but operates under more aggressive pricing and tender systems. Japan and other developed markets add revenue but face local reimbursement controls.
Geographic risk differs by region:
| Region |
Primary commercial issue |
| United States |
Biosimilar timing, PBM rebates and formulary placement |
| Europe |
National pricing, tendering and follow-on biologic competition |
| Japan |
Reimbursement controls and local market access |
| Emerging markets |
Lower price, access expansion and distributor economics |
A U.S. biosimilar launch would likely have the largest effect on Lilly’s operating profit. European erosion may occur earlier or more gradually depending on local patent and reimbursement rules.
What licensing deals affect ixekizumab?
Taltz is primarily an internally developed Eli Lilly product. No major third-party licensing transaction is central to the commercial identity of ixekizumab in the way that certain partnered biologics depend on external licensors or co-development agreements.
Lilly’s control over development, manufacturing and commercialization supports margin retention and gives the company flexibility in lifecycle management. The absence of a major royalty burden is favorable to product economics, although Lilly still incurs substantial manufacturing, sales, medical-affairs and market-access costs.
What is the investment and commercial outlook for Taltz?
Taltz is a mature, high-value immunology franchise with declining growth sensitivity and rising lifecycle risk. Its value is supported by a large revenue base, multiple indications and durable physician adoption. Its valuation is constrained by competition from newer mechanisms and the finite period before biosimilar exposure.
The key indicators for investors and licensing teams are:
- Annual Taltz revenue and U.S. net price.
- Prescription growth by dermatology and rheumatology.
- Share relative to Skyrizi, Tremfya, Cosentyx and Bimzelx.
- International revenue growth.
- New label expansions.
- FDA Purple Book activity.
- Biosimilar clinical or regulatory disclosures.
- Patent litigation and settlement filings.
- Lilly’s gross-to-net discounting.
- Patient persistence and switching rates.
A reasonable commercial assessment is that Taltz should remain a multibillion-dollar product through the late 2020s, but its growth profile is weaker than that of newer immunology and metabolic products. The largest inflection point is the transition from branded competition to follow-on biologic competition after the principal U.S. exclusivity period.
Key Takeaways
- Taltz generated approximately $2.48 billion in revenue in 2023.
- Revenue growth accelerated through 2022 and stabilized in 2023.
- The drug competes most directly with Cosentyx, Skyrizi, Tremfya and Bimzelx.
- IL-23 inhibitors are the largest share threat in plaque psoriasis.
- Taltz has FDA approvals across psoriasis, psoriatic arthritis and axial spondyloarthritis.
- U.S. biologic exclusivity runs approximately to 2028, subject to applicable adjustments.
- Taltz is governed by the Purple Book and BPCIA framework, not the conventional Orange Book paragraph IV system.
- No FDA-approved ixekizumab biosimilar had been identified through June 30, 2024.
- The patent estate covers antibody, formulation, manufacturing and method-of-use claims.
- Taltz is likely to remain a large cash-flow product, but its long-term value depends on biosimilar timing and Lilly’s ability to defend share.
FAQs
How is ixekizumab administered?
Taltz is administered by subcutaneous injection. Dosing varies by indication, age group and treatment phase. The FDA-approved prescribing information governs loading and maintenance schedules.
Does ixekizumab have biosimilar competition?
No FDA-approved ixekizumab biosimilar had been identified through June 30, 2024. Future competition is possible after regulatory and patent barriers are addressed.
Is Taltz included in the Medicare drug-price negotiation program?
Taltz was not among the first group of medicines selected by CMS for the initial Medicare negotiation cycle announced in 2023. Future selection depends on statutory eligibility, negotiation cycles and product timing.
Which drug is a stronger competitor to Taltz, Skyrizi or Cosentyx?
Cosentyx is the closest mechanistic competitor because both drugs inhibit IL-17A. Skyrizi is a major commercial competitor because IL-23 inhibition has gained substantial psoriasis share and offers convenient maintenance dosing.
What is the main long-term risk to ixekizumab revenue?
The main risk is combined erosion from newer IL-23 therapies before 2028 and biosimilar or follow-on biologic competition after the principal U.S. exclusivity period.
References
-
Eli Lilly and Company. (2024). 2023 annual report and Form 10-K. Indianapolis, IN: Author.
-
Eli Lilly and Company. (2023). 2022 annual report and Form 10-K. Indianapolis, IN: Author.
-
Eli Lilly and Company. (2022). 2021 annual report and Form 10-K. Indianapolis, IN: Author.
-
U.S. Food and Drug Administration. (2024). Taltz (ixekizumab) prescribing information. Silver Spring, MD: U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. Silver Spring, MD: U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar product information. Silver Spring, MD: U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2016). FDA approves new treatment for moderate-to-severe plaque psoriasis. Silver Spring, MD: U.S. Department of Health and Human Services.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003. Washington, DC.
